Research analysts at Cantor Fitzgerald assumed coverage on shares of Trulieve Cannabis (NYSE:TRLV – Get Free Report) in a report issued on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $15.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 70.69% from the stock’s current price.
A number of other analysts also recently issued reports on TRLV. Zacks Research upgraded Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. Wall Street Zen cut shares of Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings began coverage on shares of Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.00.
Read Our Latest Stock Analysis on TRLV
Trulieve Cannabis Trading Down 0.0%
Insider Buying and Selling
In related news, CEO Kim A. Rivers sold 400,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $8.17, for a total value of $3,268,000.00. Following the transaction, the chief executive officer owned 1,913,724 shares of the company’s stock, valued at $15,635,125.08. This represents a 17.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,699,007 shares of company stock valued at $14,661,355 over the last quarter. 3.79% of the stock is owned by corporate insiders.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.
Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.
Further Reading
- Five stocks we like better than Trulieve Cannabis
- Buyback Boom: These 3 Companies Are Betting Billions on Their Own Stocks
- Costco’s Cooling Comp Sales Keep Stock Stuck in Neutral for Now
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
